GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

GB Sciences, Inc.

3550 West Teco Avenue
Las Vegas, NV 89118
United States

Full Time Employees60

Key Executives

NameTitlePayExercisedYear Born
Mr. John C. PossChairman, CEO & Pres341.03kN/A1948
Ms. Ksenia GriswoldCOO, CFO, VP & Controller226.15kN/A1983
Dr. Andrea Small-Howard M.B.A., Ph.D., MBAChief Science Officer & Director135.38kN/A1969
Mr. Krin Ellery KuetheSr. VP of Cultivation471.18kN/A1984
Mr. John B. DavisGen. Counsel & Exec. VPN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


GB Sciences, Inc. focuses to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for various ailments. The company is developing technologies in plant biology, cultivation and extraction techniques, which are combined with biotechnology; and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. GB Sciences, Inc. has an agreement with Growblox Sciences, Puerto Rico, LLC that grants the right to its technology and intellectual property. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.

Corporate Governance

GB Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.